Question · asked by 1 review
Anti‐VEGF vs sham: QoL
- Population
- macular oedema secondary to branch retinal vein occlusion
- Intervention
- Anti‐VEGF
- Comparison
- sham
- Outcome
- QoL
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Anti‐VEGF vs sham Mean change in quality of life (QoL) at 12 months on the National Eye Institute Visual Functioning Questionnaire‐25 (VFQ‐25) (scored 0 to 100) (higher score is better quality of life) · macular oedema secondary to branch retinal vein occlusion Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion (2020) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 281 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Anti‐VEGF vs laser · people with BRVO · 1 review
- Anti‐VEGF vs steroids · people with BRVO · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.